Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keppra in Alcohol Withdrawal Syndrome
NCT00146471Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levetiracetam in alcohol withdrawal syndrome (AWS), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Reduction of the total needed amount of diazepam. Started Jan 2006; status: completed.
02
Drugs
levetiracetam
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on NCT00146471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146471.